2 High-Yield Stocks That Can Survive If the AI Crowd Finally Blinks

AI concentration is making non-AI yield stands more attractive

Why yield matters in a concentrated market

The market is not just AI-heavy; it is increasingly AI-driven. AI-related stocks now make up ~47% of the S&P 500's market cap, near a recent high, and broad-index performance has been led by a small group of giants: the top 20 companies account for 49% of the index and have delivered 64% of its five-year return. In that kind of market, average investors are not getting true diversification. They are getting a concentrated bet.

That concentration is what makes yield more relevant now. AI remains the dominant theme for equities, and data-center construction alone commanded more than $500 billion in 2025, with total AI infrastructure spending projected between $5 trillion and $8 trillion by 2030. If that momentum holds, the theme can keep driving returns. But if it wobbles, portfolios built around one winning narrative may feel it quickly. That is when businesses with steadier cash returns can matter-not because they are exciting, but because they behave differently.

At the same time, income opportunities have become harder to find. The S&P 500 dividend yield has sunk toward all-time lows near 1%, while tech spending remains massive and its long-term payoff is still being proven. That backdrop helps explain why two unglamorous, non-AI businesses-Clorox and Altria-can still make sense for investors who want income, durability, and less exposure to the market's narrow leadership.

Why investors are looking outside the AI trade

Clorox does not ride the AI cycle, and that is both the problem and the opportunity. In a market where AI-related stocks now reflect ~47% of the S&P 500's market cap, stocks that are not part of the winning theme often struggle for attention. Clorox's appeal is simpler: household demand, brand presence, and steadier margins rather than cloud growth or data-center buildout.

That is also why its valuation discount can last longer than investors hope. When portfolio managers are chasing the current winner, a stable defensive business can look like underperformance in the moment-even if it is resilience in practice.

Why the income case still matters

The broader market backdrop helps explain the setup. With the S&P 500 dividend yield has sunk toward all-time lows near 1%, investors are being pushed to look beyond the AI mega-theme. Clorox may not be a high-beta rebound name. It is, at minimum, a way to own a cash-generating business with less dependence on whether the next AI earnings report comes in hot.

The real question: cheap because it is safe, or safe because it is ignored?

• Bull case: in a concentrated market, steady dividend growers can remain cheap until a shock or slowdown forces rotation toward less crowded holdings.
• Bear case: if AI keeps taking up liquidity and mindshare, Clorox may remain underowned, with upside limited by the market's narrow taste.

Altria's yield is large, but the stigma is not arbitrary

Why the discount can stay rational

Altria is the more uncomfortable choice, and that discomfort is part of the thesis. Its forward yield of roughly 7.7% is hard to ignore, but it comes with a heavier emotional and fundamental load than Clorox. The stock pays well now, yet it still sits outside the AI concentration trade.

Bears are right to note the risks. Tobacco faces downside risk in a broader market context where stressed conditions can hit even seemingly defensive businesses. That helps explain why the market keeps demanding a discount: regulatory pressure, volume decline, litigation, and policy risk can all weigh on sentiment. A long dividend record is helpful, but it is not absolute protection-Walgreens cut its dividend nearly in half in 2024, which is a reminder that history alone does not guarantee safety.

What has to go right for the bull case

The Altria bull case is narrower than simply buying the stigma. It is that the company may offer strong immediate income and some rerating potential if investors start valuing yield and cash return more than they value being near the market's center of attention.

The market backdrop remains extreme. BlackRock sees AI infrastructure spending of $5 trillion to $8 trillion by 2030, even as other sectors have erased -$1 trillion of their market cap. If that dynamic continues, Altria remains a niche story. If it changes, high-yield names outside the AI trade could become easier for investors to own.

• Bull case: investors grow fatigued of the crowded winner, start paying for yield again, and reward a business that offers strong cash return without adding to AI concentration.
• Bear case: stigma deepens, legal or policy pressure worsens, and the yield stops being a cushion and starts looking like a value trap.

For investors who want more income than Clorox likely provides upfront, Altria remains the higher-yield, higher-friction option. The opportunity exists because market psychology has not fully caught up with the risks of owning too much of the same winner.